(Press-News.org) PHILADELPHIA – A next-generation “armored” CAR T cell therapy showed promising results in a small study of patients whose B-cell lymphomas continued to resist multiple rounds of other cancer treatments, including commercially available CAR T cell therapies. The new therapy diminished cancer in 81 percent of patients and resulted in complete remission in 52 percent, with some of the earliest patients treated experiencing durable remission for two years or more. The findings, led by researchers in the Perelman School of Medicine at the University of Pennsylvania, were published today in the New England Journal of Medicine.
While CAR T cell therapy—a personalized form of cancer immunotherapy first successfully developed by Carl June, MD, and his team at Penn—has revolutionized treatment for many blood cancers, more than 50 percent of patients with lymphoma who receive currently available CAR T cell therapy do not experience a long-term remission. Of the seven FDA-approved CAR T cell therapy products, four are used to treat various types of B-cell lymphomas. For those whose cancers return or become resistant after CAR T cell therapy, the prognosis is unfortunately poor, with few options left. Previous research has shown that re-treating these patients with existing CAR T cell therapies does not work well.
“I’m thrilled that this new generation of CAR T cell therapy, created here at Penn, was highly effective in patients who have already tried everything available to treat their lymphoma,” said Jakub Svoboda, MD, an associate professor of Hematology-Oncology, who led the clinical trial at Penn Medicine’s Abramson Cancer Center. “It’s also encouraging to see that the toxicity of this novel product was not different than what we already see with commercial CARs.”
The addition of IL18 did not result in any new or unexpected safety concerns beyond the known side effects of CAR T cell therapy, including cytokine release syndrome (CRS) and neurotoxicity, which were managed successfully. The researchers also found that the type of CAR T cell therapy patients previously received may impact the efficacy of huCART19-IL18.
New strategy adds a cytokine to make CAR T cells more effective
The 21 patients in this phase I clinical trial had received a median of seven other therapies prior to enrolling in the study, and all but one had already tried a CAR T cell therapy approved for their cancer type. When cancer continues to advance despite aggressive treatment like this, it’s due in part to immune suppression and T cell exhaustion that make anti-cancer therapies less effective.
To combat these challenges, a team led by June, the Richard W. Vague Professor in Immunotherapy, developed a new, “armored” CAR T cell product called huCART19-IL18. Like most other CAR T cell products for lymphoma, it targets a surface antigen called CD19. However, this version was further modified to secrete interleukin 18 (IL18), a pro-inflammatory cytokine capable of enhancing the immune system, by recruiting additional immune cells to support the engineered T cells. In doing so, it further protects the CAR T cells and promotes their ability to attack the cancer cells, June explained.
This study represents a significant development in the ongoing evolution of CAR T cell therapy, as the first time a cytokine-enhanced CAR T has been tested in patients with blood cancer. By analyzing blood samples from patients after they received treatment, the research team found strong evidence indicating that adding IL18 to the CAR T cells contributed to the robust response rates.
“Based on these results, we believe that incorporating cytokine secretion into CAR T cell design will have broad implications for enhancing cellular therapies, even beyond blood cancers,” June said. “With longer T cell persistence and expansion, this strategy could be powerful in settings where CAR T hasn’t performed as well, such as solid tumors.”
The production of huCART19-IL18 also uses a process, developed by Penn’s Center for Cellular Immunotherapies, that shortens the manufacturing time for the CAR T cells to just three days. For patients with aggressive, fast-growing cancers, this means being able to begin CAR T cell therapy quicker than is currently possible with standard manufacturing times of nine to 14 days. Previous research has hinted that the shortened manufacturing time also may enhance the potency of the T cells.
Driving research forward
The research team already has several other clinical trials planned, including studies that will expand huCART19-IL18 to patients with acute lymphocytic leukemia (ALL) and chronic lymphocytic leukemia (CLL). Another trial for non-Hodgkin’s lymphoma using a similar IL18-armored CAR T cell product is currently enrolling patients. On the manufacturing side, the team is partnering with a Penn spinout company to improve the process for how these CAR T cells are created and expanded in the laboratory before being reinfused into the patient.
“We know that bringing this type of new therapy from the lab bench to the patient bedside is only possible at a place like Penn Medicine, thanks to our courageous patients and the teamwork between our scientific and clinical teams,” Svoboda said. “With the biopsies and cytokine data from this trial, we’ve gained a wealth of information about patients relapsing after CAR T cell therapy that could help researchers better understand the science of CAR T cell therapy relapse in general.”
The study was made possible with institutional funding from the University of Pennsylvania. Svoboda previously reported interim outcomes data from the study at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and the 2024 European Hematology Association (EHA) Congress.
Information for patients interested in joining a clinical trial: visit Penn Medicine's Abramson Cancer Center Clinical Trial Information Service online or call 1-855-216-0098 to speak to a clinical trial navigator.
###
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System and Penn’s Raymond and Ruth Perelman School of Medicine, founded in 1765 as the nation’s first medical school.
The Perelman School of Medicine is consistently among the nation's top recipients of funding from the National Institutes of Health, with $580 million awarded in the 2023 fiscal year. Home to a proud history of “firsts” in medicine, Penn Medicine teams have pioneered discoveries and innovations that have shaped modern medicine, including recent breakthroughs such as CAR T cell therapy for cancer and the mRNA technology used in COVID-19 vaccines.
The University of Pennsylvania Health System’s patient care facilities stretch from the Susquehanna River in Pennsylvania to the New Jersey shore. These include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Doylestown Health, Lancaster General Health, Penn Medicine Princeton Health, and Pennsylvania Hospital—the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is an $11.9 billion enterprise powered by nearly 49,000 talented faculty and staff.
END
Enhanced CAR T cell therapy offers new strategy for lymphoma
Next-generation CAR T cell therapy works where other CAR T cell therapies have failed
2025-05-07
ELSE PRESS RELEASES FROM THIS DATE:
Researchers identify measure of pulse rate that can predict faster cognitive decline in older adults
2025-05-07
Healthy hearts are adaptable, and heartbeats exhibit complex variation as they adjust to tiny changes in the body and environment. Mass General Brigham researchers have applied a new way to measure the complexity of pulse rates, using data collected through wearable pulse oximetry devices. The new method, published in Journal of the American Heart Association, provides a more detailed peek into heart health than traditional measures, uncovering a link between reduced complexity and future cognitive decline.
“Heart rate complexity is a hallmark of healthy physiology,” said senior author Peng Li, ...
Discovery of dopamine receptors in a previously overlooked part of the brain sheds light on the complex circuitry for anxiety and depression
2025-05-07
Mount Sinai researchers have discovered distinct roles for two dopamine receptors located on nerve cells within the portion of the brain that controls approach vs. avoidance behavior. These receptors potentially influence anxiety and mood disorders whose origins are still unclear.
The team characterized the function of D1 and D2 dopamine receptors in the ventral hippocampus of mice, a region involved in the regulation of emotions and stress responses. Their work expands the field’s knowledge of dopamine signaling beyond its well-known actions in other brain regions that influence reward and motivation, and sets the stage ...
No one to play with? UCLA’s PEERS for Preschoolers program is changing that
2025-05-07
Imagine this: You watch your child at the playground, their eyes lighting up as they approach a group of laughing kids. But instead of welcoming them in, the children turn away. No invitation to join, no shared smiles—just an invisible barrier keeping your child on the outside looking in.
For parents, the pain of seeing their child struggle to make friends can be heartbreaking. Every parent wants their child to be included, to experience the joy of companionship, and to feel the warmth of a friendly hand reaching out to pull them into play. But what happens when social skills don’t come naturally? Where do parents turn when their child is struggling to navigate the complex ...
New method provides fresh insights into insect decline
2025-05-07
It has long been known that agriculture contributes to the decline in insect biodiversity. The loss of host plants, frequent mowing, and pesticide use all deprive many species of their habitats.
Now, a research team from the Julius-Maximilians-Universität Würzburg (JMU) has discovered—using innovative analytical methods—that the impact of agricultural land use on insect diversity is even more dramatic than previously assumed. The findings are based on an analysis of insect species from 400 families collected across a wide range of habitats in Bavaria.
The study was led by Professor Jörg Müller, Chair of Conservation ...
Foot traffic can predict COVID-19 spread in New York City neighborhoods
2025-05-07
A new study published in the journal PLOS Computational Biology reveals how foot traffic data from mobile devices can enhance neighborhood-level COVID-19 forecasts in New York City. The research, led by researchers at Columbia University Mailman School of Public Health and Dalian University of Technology, provides a novel approach to predicting the spread of the SARS-CoV-2 virus and improving targeted public health interventions during future outbreaks.
The COVID-19 pandemic hit New York City hard, with infection rates varying dramatically across neighborhoods. ...
Janice R. Lachance, J.D., FASAE selected for top position of global earth and space science association
2025-05-07
WASHINGTON — The American Geophysical Union Board of Directors and Executive Search Committee is pleased to announce AGU’s new Executive Director and CEO will be Janice R. Lachance, J.D., Fellow of the American Society of Association Executives and the National Academy of Public Administration.
“Janice has served as an exceptional interim Executive Director and CEO during the last two years, said AGU President Brandon Jones, Ph.D. “She has demonstrated the leadership qualities ...
Eating ultra processed foods may speed up early signs of Parkinson's disease
2025-05-07
MINNEAPOLIS — People who eat more ultra processed foods like cold breakfast cereal, cookies and hot dogs are more likely to have early signs of Parkinson’s disease when compared to those who eat very few ultra processed foods, according to a study published in the May 7, 2025, online in Neurology®, the medical journal of the American Academy of Neurology. The study does not prove that eating more ultra processed foods causes early signs of Parkinson’s disease; it only shows an association.
Researchers looked for signs of prodromal Parkinson’s disease, which is the earliest stage, when neurodegeneration ...
Sleep apnea during REM sleep linked to memory-related brain changes
2025-05-07
MINNEAPOLIS — Obstructive sleep apnea, a condition that causes lower oxygen levels during sleep, is linked to degeneration of brain regions associated with memory through damage to the brain’s small blood vessels, according to a study published May 7, 2025, online in Neurology®, the medical journal of the American Academy of Neurology. The study found the brain changes were strongly associated with the severity of drops in oxygen levels during rapid eye movement (REM) sleep. The study does not prove that sleep apnea causes this degeneration; it only shows an association.
Obstructive sleep apnea occurs when throat muscles relax during sleep, blocking ...
Vaccines of the future: harnessing the immune system for long-lasting protection
2025-05-07
WEHI scientists have uncovered a promising new way to enhance the effectiveness of vaccines by tapping into the potential of a specific type of immune cell, opening the door to long-lasting vaccines for viruses and enhanced cancer therapies.
The WEHI-led study used a novel approach combined with cutting-edge mRNA vaccine technology to increase the formation of a type of T cell which has remarkable self-renewing capacity and can remember threats for years and even decades.
The mouse-based study, published in the ...
GigaScience Press wins inaugural Crossref Metadata Award for highest quality publishing metadata standards for their journal GigaByte
2025-05-07
GigaScience Press is a winner of the inaugural Crossref Metadata Awards, recognising efforts in scholarly publishing metadata completeness and enrichment in their journal, GigaByte. Thanks to River Valley Technology’s state-of-the-art publishing platform, the journal was selected amongst over the nearly 150,000 journals from 22,000 members using Crossref infrastructure for having the highest metadata completeness in the small publishers category.
Presented for the first time at the Crossref Midyear ...
LAST 30 PRESS RELEASES:
Eating ultra-processed foods may harm your health
Major US cities are sinking
New study traces sharp regional shifts in ischemic heart disease burden — a global warning signal
Too fast to see
All of the biggest U.S. cities are sinking
Database reveals vital ocean links to aid conservation
Robotic dog mimics mammals for superior mobility on land and in water
Mammal’s lifespans linked to brain size and immune system function, says new study
Top EU food & agri institutes launch new science alliance
How to reduce global CO2 emissions from industry
Nature visits can improve well-being disparities among urban dwellers
Silent scorpion-sting epidemic in Brazil driven by urbanization and climate change
GP-led talking therapy eases PTSD symptoms after critical illness
Removing ovaries and fallopian tubes linked to lower risk of early death among breast cancer patients with BRCA cancer genes
The Lancet: Nearly half of sexual abuse first happens at age 15 or younger
Satellites observe glacier committing “ice piracy”
Non-inherited genes affect children’s development
Social media platform tailoring could support more fulfilling use, study finds
The hope for detecting Parkinson’s disease much earlier with a simple brain scan
MRI breakthrough could revolutionize diagnosis of common heart problem aortic stenosis
Enhanced CAR T cell therapy offers new strategy for lymphoma
Researchers identify measure of pulse rate that can predict faster cognitive decline in older adults
Discovery of dopamine receptors in a previously overlooked part of the brain sheds light on the complex circuitry for anxiety and depression
No one to play with? UCLA’s PEERS for Preschoolers program is changing that
New method provides fresh insights into insect decline
Foot traffic can predict COVID-19 spread in New York City neighborhoods
Janice R. Lachance, J.D., FASAE selected for top position of global earth and space science association
Eating ultra processed foods may speed up early signs of Parkinson's disease
Sleep apnea during REM sleep linked to memory-related brain changes
Vaccines of the future: harnessing the immune system for long-lasting protection
[Press-News.org] Enhanced CAR T cell therapy offers new strategy for lymphomaNext-generation CAR T cell therapy works where other CAR T cell therapies have failed